Crossref
Neoadjuvant chemotherapy should only be considered in patients with cT3-T4a muscle-invasive bladder cancer
Uro-Technology Journal · 2024
DOI: 10.31491/utj.2024.09.025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Uro-Technology Journal, 2024. Verfasst von Sytse C. van Beek und 3 weiteren Autor:innen.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Beek, S. C. V., Ginkel, N. V., Boormans, J. L., & Vis, A. N. (2024). Neoadjuvant chemotherapy should only be considered in patients with cT3-T4a muscle-invasive bladder cancer. Uro-Technology Journal. https://doi.org/10.31491/utj.2024.09.025
Vancouver
Beek SCV, Ginkel NV, Boormans JL, Vis AN. Neoadjuvant chemotherapy should only be considered in patients with cT3-T4a muscle-invasive bladder cancer. Uro-Technology Journal. 2024. doi:10.31491/utj.2024.09.025
BibTeX
@article{Beek2024,
author = {Beek, Sytse C. van and Ginkel, Noor van and Boormans, Joost L. and Vis, André N.},
title = {Neoadjuvant chemotherapy should only be considered in patients with cT3-T4a muscle-invasive bladder cancer},
journal = {Uro-Technology Journal},
year = {2024},
doi = {10.31491/utj.2024.09.025}
}
EUVIMED